Regulations

© GettyImages/Pheelings Media

FDA rebuff for Keytruda in breast cancer indication

By Jane Byrne

A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.

(VectorInspiration/iStock via Getty Images Plus)

Latest FDA COVID-19 updates and activity

By Jenni Spinner

The federal agency continues to keep researchers, pharma firms and citizens apprised of current happenings and research related to the virus and pandemic.

Follow us

Product Innovations

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...